Mogoş V, Zbranca E, Strat V, Diaconescu M R, Chifan M, Florea N, Costăchescu G, Găleşanu M R, Rusu V, Georgescu G
Clinica Endocrinologică, Universitatea de Medicină şi Farmacie Gr. T. Popa, Iaşi.
Rev Med Chir Soc Med Nat Iasi. 1995 Jan-Jun;99(1-2):72-81.
We have analysed factors that influenced on the patient survival in 195 cases of thyroid cancer. The survival is essentially influenced by the histology, the papillary forms (survival after 15 years: 83.1-93%) and follicular cancers (survival after 15 years: 84-94%) having an excellent evolution. The non-differentiated and mixed cancers have a very severe prognosis that is independent of the complex therapy that have been used (survival after 5 years: 17.1% in non-differentiated forms and 32.5% in mixed ones). The prognosis is better in subjects under the age of 45 and in female subjects. The cancers in the 1-st and 2-nd stage of tumor extension have a better evolution that those in the 3-rd stage. In differentiated cancers, the total or subtotal thyroidectomy followed by radioiodine administration determine the best survival.
我们分析了影响195例甲状腺癌患者生存的因素。生存主要受组织学影响，乳头状癌（15年后生存率：83.1% - 93%）和滤泡状癌（15年后生存率：84% - 94%）预后良好。未分化癌和混合性癌预后很差，且与所采用的综合治疗无关（未分化型5年后生存率：17.1%，混合型为32.5%）。45岁以下患者和女性患者预后较好。肿瘤扩展处于第一和第二阶段的癌症比第三阶段的预后更好。在分化型癌症中，全甲状腺切除或次全甲状腺切除后给予放射性碘治疗可获得最佳生存率。
